{"title": "Browse News", "author": null, "url": "https://www.biospace.com/news/", "hostname": "biospace.com", "description": "Breaking news from the biotech, clinical research and pharmaceutical industries. BioSpace is The Home of the Life Sciences Industry.", "sitename": "biospace.com", "date": "2023-09-11", "cleaned_text": "Browse News Filter News Found 783,446 articles - The regulator Monday approved the companies' supplemental Biologics License Applications for their respective mRNA shots formulated to more closely target currently circulating variants. - The first-in-class antibody-drug conjugate\u2014in combination with Merck's Keytruda\u2014has shown promising results in a Phase II study of patients with metastatic non-small cell lung cancer. - Following a Phase II review, Novartis has cut the development of a gene therapy candidate for geographic atrophy. In June, the company sold a dry eye disease drug to Bauch + Lomb for $1.75 billion. - The California pharma is building up to its first-ever approval with promising late-stage data for its once-daily investigational acromegaly pill paltusotine, an alternative to the injectable standard of care. - The collaboration, which includes an upfront payment of $120 million to Immatics, pairs Moderna's mRNA technology with Immatics' T-cell receptor platform for cancer treatment. - With a potential combined market value of $30 billion, BioSpace takes a deep dive into the Phase III data supporting Eisai and Biogen's Leqembi and Eli a delay, GSK expects an FDA verdict for its myelofibrosis candidate, while Alnylam gears up for an advisory committee meeting discussing patisiran in cardiomyopathy of ATTR amyloidosis. - A thorough reassessment of the confounders between FibroGen's trials is necessary to salvage the company's Duchenne Muscular Dystrophy program and regain investor confidence. - Keep up with the regulator's latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals. - [Zynex Announces Share Repurchase Program](/article/releases/zynex-announces-share-repurchase-program/) 9/11/2023 Zynex, Inc today announced that its board of directors approved a program to repurchase $10.0 million of the Company's common stock. - [Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer's Disease](/article/releases/cassava-sciences-announces-science-publication-that-confirms-mechanism-of-action-of-simufilam-a-novel-drug-candidate-for-people-with-alzheimer-s-disease/) 9/11/2023 Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced the publication of new research that confirms the biological activity of simufilam. - [Moderna and Immatics Announce Strategic Multi-Platform biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. - [Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Initial primary endpoint data anticipated in late 2023 or early Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the first participant has been dosed in the CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life extended monoclonal antibody, for the prevention of symptomatic COVID-19. - [Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced clinical data from the discontinued Phase 3 ARTEST clinical trial of enobosarm monotherapy for the 3rd line or greater in the metastatic setting of AR+ER+HER2- breast cancer. - [Therapeutic Solutions International Reports Landmark Advancement in Stem Cell Therapy of Frontotemporal Dementia](/article/releases/therapeutic-solutions-international-reports-landmark-advancement-in-stem-cell-therapy-of-frontotemporal-dementia/) 9/11/2023 Therapeutic Solutions International, Inc. (TSOI), announced today the development of a new therapeutic approach for treatment of Frontotemporal Dementia, by combining the activation of endogenous anti-inflammatory cells in the nervous system. - [EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023](/article/releases/eyepoint-pharmaceuticals-reports-positive-masked-safety-update-for-lead-product-candidate-eyp-1901-in-ongoing-pavia-and-davio-2-phase-2-clinical-trials-as-of-september-1-2023/) 9/11/2023 EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced positive interim masked safety data for its lead product candidate EYP-1901 from the Company's ongoing Phase 2 PAVIA trial evaluating EYP-1901 as a potential nine-month treatment for moderately-severe to severe non-proliferative diabetic retinopathy (NPDR) and DAVIO 2 trial as a potential six-month sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD). - [TAGRISSO\u00ae (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial](/article/releases/tagrisso-osimertinib-plus-chemotherapy-extended-median-progression-free-survival-by-nearly-9-months-in-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial/) 9/11/2023 Positive results from the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO\u00ae (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor cell lung cancer (NSCLC). - [APRINOIA Therapeutics Announces Strategic Investment From company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases, headquartered in Cambridge, MA, is pleased to announce the strategic investment by the Alzheimer's Drug Discovery Foundation (ADDF) of approximately $4.4M. - [Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse](/article/releases/marker-therapeutics-announces-complete-response-in-first-lymphoma-patient-treated-with-mt-601-after-car-t-relapse/) Therapeutics, Inc. (Nasdaq: is focusing on developing T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. - [Treatment with RYBREVANT\u00ae (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer](/article/releases/treatment-with-rybrevant-amivantamab-vmjw-and-lazertinib-plus-chemotherapy-showed-durable-progression-free-survival-in-patients-with-previously-treated-egfr-mutated-advanced-non-small-cell-lung-cancer/) 9/11/2023 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced follow-up results from the Phase 1b/2 CHRYSALIS-2 study cohort evaluating the safety and tolerability "}